| Tazemetostat studied in …STUDIED_INderived52 of 52show fewer |
|---|
| → studied in | NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · 52 trials list this drug (20 active) | — | — | Ovarian Carcinoma,Endometrial Endometrioid Adenocarcinoma,Ovarian Clear Cell Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · 52 trials list this drug (20 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Non-Hodgkin Lymphoma,Primary Cutaneous T-Cell Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06242834Phase 2 · active not recruiting Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma · 52 trials list this drug (20 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04557956Phase 1/Phase 2 · active not recruiting Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment · 52 trials list this drug (20 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02889523Phase 1/Phase 2 · active not recruiting Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy · 52 trials list this drug (20 active) | — | — | Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04224493Phase 3 · active not recruiting A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. · 52 trials list this drug (20 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03854474Phase 1/Phase 2 · active not recruiting Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma · 52 trials list this drug (20 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155620Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · 52 trials list this drug (20 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03874455no longer available Tazemetostat Expanded Access Program for Adults With Solid Tumors · 52 trials list this drug (20 active) | — | — | Malignant Mesothelioma,Malignant Myoepithelioma,Atypical Teratoid/Rhabdoid Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04225429no longer available Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma · 52 trials list this drug (20 active) | — | — | Epithelioid Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04917042Phase 2 · active not recruiting Tazemetostat in Malignant Peripheral Nerve Sheath Tumors · 52 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05353439Phase 1 · active not recruiting Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer · 52 trials list this drug (20 active) | — | — | Lung Small Cell Carcinoma,Platinum-Resistant Lung Small Cell Carcinoma,Platinum-Sensitive Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04846478Phase 1 · active not recruiting Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC · 52 trials list this drug (20 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407283Phase 1/Phase 2 · recruiting A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer · 52 trials list this drug (20 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983965Phase 1 · terminated Study of Tazemetostat in Lymphoid Malignancies · 52 trials list this drug (20 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04241835Phase 1 · terminated A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function · 52 trials list this drug (20 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03213665Phase 2 · completed Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) · 52 trials list this drug (20 active) | — | — | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor,Hepatoblastoma,Malignant Germ Cell Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05407441Phase 1/Phase 2 · active not recruiting Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · 52 trials list this drug (20 active) | — | — | Chordoma,Atypical Teratoid/Rhabdoid Tumor,Rhabdoid Tumor of the Kidney+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05618366Phase 1 · terminated Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma · 52 trials list this drug (20 active) | — | — | Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06692452Phase 2 · withdrawn Tazemetostat Plus CHOP in 1L T-cell Lymphoma · 52 trials list this drug (20 active) | — | — | Lymphoma,Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type,Peripheral T-Cell Lymphoma, Not Otherwise Specified+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05023655Phase 2 · terminated Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation · 52 trials list this drug (20 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627232Phase 1 · recruiting Tazemetostat and Palbociclib With CPX-351for R/R AML · 52 trials list this drug (20 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04179864Phase 1/Phase 2 · terminated A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer · 52 trials list this drug (20 active) | — | — | Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04705818Phase 2 · completed Combining Epigenetic And Immune Therapy to Beat Cancer. · 52 trials list this drug (20 active) | — | — | Solid Neoplasm,Adult Solid Neoplasm,Soft Tissue Sarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05551936Phase 1/Phase 2 · active not recruiting A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma · 52 trials list this drug (20 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06068881Phase 2 · withdrawn A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation · 52 trials list this drug (20 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06575686Phase 2 · suspended Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · 52 trials list this drug (20 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04204941Phase 1 · terminated Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma · 52 trials list this drug (20 active) | — | — | Soft Tissue Sarcoma,Epithelioid Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05228158active not recruiting A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan · 52 trials list this drug (20 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02875548Phase 1/Phase 2 · completed A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study · 52 trials list this drug (20 active) | — | — | Solid Neoplasm,Malignant Mesothelioma,Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890352Phase 2 · recruiting Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · 52 trials list this drug (20 active) | — | — | Transformed Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07209163Phase 1/Phase 2 · not yet recruiting Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma · 52 trials list this drug (20 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05372354Phase 1/Phase 2 · recruiting A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma · 52 trials list this drug (20 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02601950Phase 2 · completed A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma · 52 trials list this drug (20 active) | — | — | Atypical Teratoid/Rhabdoid Tumor,Poorly Differentiated Chordoma,Rhabdoid Tumor of the Kidney+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04537715Phase 1 · completed Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels · 52 trials list this drug (20 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Solid Neoplasm,Malignant Mesothelioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05467943Phase 2 · completed Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma · 52 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05713110Phase 2 · completed A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma · 52 trials list this drug (20 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02601937Phase 1 · completed EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma · 52 trials list this drug (20 active) | — | — | Rhabdoid Tumor,Synovial Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01897571Phase 1/Phase 2 · completed Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL · 52 trials list this drug (20 active) | — | — | Solid Neoplasm,B-Cell Malignant Neoplasm,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762160Phase 2 · terminated SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma · 52 trials list this drug (20 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624113Phase 1 · terminated Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma · 52 trials list this drug (20 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05567679early Phase 1 · withdrawn A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer · 52 trials list this drug (20 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05205252Phase 1/Phase 2 · withdrawn A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. · 52 trials list this drug (20 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05604417Phase 1/Phase 2 · withdrawn Zandelisib + Tazemetostat in R/R Follicular Lymphoma · 52 trials list this drug (20 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03028103Phase 1 · completed Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients · 52 trials list this drug (20 active) | — | — | Solid Neoplasm,Mediastinal Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05152459Phase 1/Phase 2 · withdrawn Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma · 52 trials list this drug (20 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05151588Phase 2 · not yet recruiting Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma · 52 trials list this drug (20 active) | — | — | Sinonasal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03456726Phase 2 · completed Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation · 52 trials list this drug (20 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03009344Phase 1 · completed A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma · 52 trials list this drug (20 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02860286Phase 2 · completed Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma · 52 trials list this drug (20 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03217253Phase 1 · withdrawn Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction · 52 trials list this drug (20 active) | — | — | Solid Neoplasm,Malignant Solid Neoplasm,Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02220842Phase 1 · completed A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma · 52 trials list this drug (20 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |